These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 15918235)

  • 21. [Premature arteriosclerosis in HIV-infected patients? Current status].
    Hoffmann C
    Herz; 2005 Sep; 30(6):467-71. PubMed ID: 16170676
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antiretroviral therapy for patients with HIV-hepatitis B virus coinfection.
    McGovern B
    Clin Infect Dis; 2007 Apr; 44(7):1012-3; author reply 1013. PubMed ID: 17342661
    [No Abstract]   [Full Text] [Related]  

  • 23. [Coronary heart disease associated with the use of highly active antiretroviral therapy (HAART). A case report and review].
    Neumann T; Kondratieva J; Eggebrecht H; Wieneke H; Esser S; Bartel T; Erbel R
    Herz; 2005 Sep; 30(6):504-9. PubMed ID: 16170681
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The first 5 years of the family clinic for HIV at Tygerberg Hospital: family demographics, survival of children and early impact of antiretroviral therapy.
    van Kooten Niekerk NK; Knies MM; Howard J; Rabie H; Zeier M; van Rensburg A; Frans N; Schaaf HS; Fatti G; Little F; Cotton MF
    J Trop Pediatr; 2006 Feb; 52(1):3-11. PubMed ID: 15947012
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection.
    Powles T; Robinson D; Stebbing J; Shamash J; Nelson M; Gazzard B; Mandelia S; Møller H; Bower M
    J Clin Oncol; 2009 Feb; 27(6):884-90. PubMed ID: 19114688
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.
    Moore RD; Keruly JC
    Clin Infect Dis; 2007 Feb; 44(3):441-6. PubMed ID: 17205456
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment interruption in HIV therapy: a SMART strategy?
    Jülg B; Goebel FD
    Infection; 2006 Jun; 34(3):186-8. PubMed ID: 16804667
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Once-daily Kaletra approved.
    AIDS Patient Care STDS; 2005 Jul; 19(7):467. PubMed ID: 16053404
    [No Abstract]   [Full Text] [Related]  

  • 29. Cerebrovascular ischemic events in HIV-1-infected patients receiving highly active antiretroviral therapy: incidence and risk factors.
    Corral I; Quereda C; Moreno A; Pérez-Elías MJ; Dronda F; Casado JL; Muriel A; Masjuán J; Alonso-de-Leciñana M; Moreno S
    Cerebrovasc Dis; 2009; 27(6):559-63. PubMed ID: 19390181
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mortality after myocardial infarction in HIV-infected patients who have initiated HAART.
    Rasmussen LD; Gerstoft J; Kronborg G; Larsen CS; Pedersen G; Obel N
    AIDS; 2007 Apr; 21(7):873-5. PubMed ID: 17415045
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-HIV agents. Should HAART begin right after an HIV diagnosis?
    TreatmentUpdate; 2009; 21(3):2-3. PubMed ID: 19630120
    [No Abstract]   [Full Text] [Related]  

  • 32. Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort.
    Calmy A; Pinoges L; Szumilin E; Zachariah R; Ford N; Ferradini L;
    AIDS; 2006 May; 20(8):1163-9. PubMed ID: 16691068
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Idiopathic portal hypertension in patients with HIV infection treated with highly active antiretroviral therapy.
    Chang PE; Miquel R; Blanco JL; Laguno M; Bruguera M; Abraldes JG; Bosch J; Garcia-Pagan JC
    Am J Gastroenterol; 2009 Jul; 104(7):1707-14. PubMed ID: 19471257
    [TBL] [Abstract][Full Text] [Related]  

  • 34. True gynecomastia in congenitally HIV-infected children treated with antiretroviral agents.
    Manfredi R; Calza L; Chiodo F
    J Chemother; 2004 Jun; 16(3):303-5. PubMed ID: 15330330
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunologic and clinical responses to highly active antiretroviral therapy in patients with HIV infection aged >50 years.
    Cuzin L; Delpierre C; Gerard S; Massip P; Marchou B
    Clin Infect Dis; 2007 Sep; 45(5):654-7. PubMed ID: 17683004
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Timing of highly active antiretroviral therapy and chemotherapy for Kaposi's sarcoma in patients with HIV infection.
    Loke WC; Spittle MF; Mitchell S; Kulasegaram R
    Int J STD AIDS; 2006 Aug; 17(8):565-6. PubMed ID: 16925908
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-HIV agents. Unexpected dangers of drug holidays--the SMART study.
    TreatmentUpdate; 2009 Jan; 21(1):5-6. PubMed ID: 19248284
    [No Abstract]   [Full Text] [Related]  

  • 38. Triple-class antiretroviral drug resistance: risk and predictors among HIV-1-infected patients.
    Napravnik S; Keys JR; Quinlivan EB; Wohl DA; Mikeal OV; Eron JJ
    AIDS; 2007 Apr; 21(7):825-34. PubMed ID: 17415037
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Boosted Reyataz comparable to Kaletra.
    AIDS Patient Care STDS; 2005 Jan; 19(1):60. PubMed ID: 15700399
    [No Abstract]   [Full Text] [Related]  

  • 40. Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study.
    Cozzi-Lepri A; Phillips AN; Clotet B; Mocroft A; Ruiz L; Kirk O; Lazzarin A; Wiercinska-Drapalo A; Karlsson A; Lundgren JD;
    AIDS; 2008 Oct; 22(16):2187-98. PubMed ID: 18832882
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.